E-Mail
Credit: University of Cincinnati
PORTLAND, OR - A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn t live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens, according to trial results published in
JAMA Oncology.
While the trial findings did not show a direct patient benefit, they do show that it s possible to safely administer chemotherapy prior to pancreatic cancer surgery. They also pave the way for better treatment testing for this notorious killer. With no symptoms in the early stages, and few effective therapies, pancreatic cancer is the fourth-most deadly cancer type in the United States. According to the American Cancer Society, only 20 percent of pancreatic cancer patients are alive one year after diagnosis. After five years, only about 7 percent are alive.
Deal Ticker: UT Southwestern Leases Space at Visionary Project Pegasus Park
Plus Trammell Crow Co. plans new Allen multifamily project, Stanton Road Capital continues Dallas office expansion, and more.
Share your top deals by emailing Real Estate Editor Bianca R. Montes at [email protected].
The University of Texas Southwestern Medical Center has signed a 180,000-square-foot lease at visionary project Pegasus Park. UT Southwestern will occupy six floors in the tower building.
Located at 3000 Pegasus Park Drive, Pegasus Park is developed as a life sciences hub for North Texas. The campus spans 23 acres and consists of more than 750,000 square feet across multiple buildings, including an 18-story office tower. Pegasus Park will be a mixed-use collaborative ecosystem and office campus designed to bolster local biotech, social impact, and corporate innovation. Construction is underway to transform the former oil industry campus into a future-focused center. Pegasus Park campus is
The highly contagious variant of the coronavirus first seen in the United Kingdom will become the dominant strain in the United States within about two
Combination treatment for methamphetamine use disorder shows promise in NIH study
A combination of two medications, injectable naltrexone and oral bupropion, was safe and effective in treating adults with moderate or severe methamphetamine use disorder in a double-blind, placebo-controlled Phase III clinical trial. The findings suggest this combination therapy may be a promising addition to current approaches to treatment, such as cognitive behavioral therapy and contingency management interventions, for a very serious condition that remains difficult to treat and overcome. The research, published today in
The New England Journal of Medicine, was conducted at multiple sites within the National Institute on Drug Abuse Clinical Trials Network (NIDA CTN). NIDA is part of the National Institutes of Health.
The highly contagious variant of COVID-19 first seen in the UK will become the dominant strain in the US within about two months, its rapid spread heightening the urgency of getting people vaccinated, the CDC predicted in its most sobering warning yet about mutations in the virus.